Pandemic Delayed Some FDA Plant Inspections, Product Approvals
(Bloomberg) -- Pandemic disruptions severely hampered U.S. regulators' ability to inspect drug and device makers' manufacturing plants, delaying at least 68 applications for approval to market new products, according to a Food and Drug Administration review.
Seven of the delayed applications were mission-critical, meaning they represented a medical advancement, the agency said Wednesday in its report, and six of those were for new drugs. The delayed applications were among 600 where the FDA required a factory inspection before approval decisions.
Inspection woes at the agency have left health investors nervous about clearances of new drugs and devices that impact companies' bottom lines. Hobbled by travel and social-distancing restrictions during the height of the pandemic, the agency is slowly regaining the ability to conduct mostly domestic inspections and may make increasing use of virtual factory visits to fill the void, Acting FDA Commissioner Janet Woodcock said.
“Our report shows all the warts, here's what happened during the pandemic, but we did a lot,” she said in an interview. “I think our people really rose to the occasion.”
Inspections for the seven delayed mission-critical applications are expected to be completed by the end of September, according to the report. FDA dind't give the names of the delayed products.
The regulator also will have to find ways to make up about 1,000 routine surveillance inspections of drug and biologic plants it hasn't been able to perform during the fiscal year that started in October. These inspections insure quality of products that have already been cleared.
Severe Pressure
The mission-critical inspections that did occur put severe pressure on agency staff. Before Covid shots were available, inspectors traveled unvaccinated with quarantine periods on both ends of their trips. Woodcock said she didn't know of any inspectors who came down with Covid after an inspection trip.
The FDA did 59 mission-critical inspections for drugs and biologics between March 2020 and March 2021, according to the report. These included inspections for products that represent medical advancements as well as treatments for Covid-19 and follow-up based on product recalls.
Some companies whose Covid shots have been authorized for emergency use are now planning to file for full approval, and among the regulator's top priorities will be inspections of vaccine plants that haven't recently been visited.
Virtual inspections that were used increasingly during the pandemic represent a potential way to hasten the inspection process for less-critical products, Woodcock said.
The agency completed 159 prioritized domestic inspections of drug and biologic facilities between March 2020 and March 2021, according to the report.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.